MedTrace Logo

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

NCT04416438 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1793

Last updated 2022-10-18

No results posted yet for this study

Summary

The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.

Conditions

  • Myeloproliferative Neoplasm
  • COVID-19 Infection

Sponsors & Collaborators

  • French Intergroup of Myeloproliferative syndromes

    collaborator UNKNOWN

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Jean-Jacques KILADJIAN, Pr · FIM

  • Laurence LEGROS, Dr · FIM

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2021-12-31
Completion
2022-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416438 on ClinicalTrials.gov